Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. by Coombs, L. M. et al.
Br.~~~~~~~~~~~ J.Cne 19) 3 0-0 ©McilnPesLd,19
Amplification and over-expression of c-erbB-2 in transitional cell
carcinoma of the urinary bladder
L.M. Coombs" 2, D.A. Pigott', E. Sweeney3, A.J. Proctor', M.E. Eydmann', C. Parkinson4
& M.A. Knowles'
'Epithelial Carcinogenesis Laboratory, Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 OTL; 2Department of
Urology, Middlesex Hospital, London; 3Department ofHistopathology, University College and Middlesex School ofMedicine,
London; and 4Institute ofUrology, London, UK.
Summary The structure and expression of the proto-oncogene c-erbB-2 was studied in 86 patients with
transitional cell carcinoma. Initial tissue samples comprised 37 grade 1, 32 grade 2 and 13 grade 3 tumours
and four cases of carcinoma in situ. At the time of this first tumour sample, amplification of the c-erbB-2 gene
was demonstrated by Southern blotting in 1/37 grade 1, 5/32 grade 2 and 6/13 grade 3 tumours (0.005<
P<0.01). Tumour 're-occurrences' were obtained from 23 of these patients on one or more occasions.
Amplification was detected in re-occurrences from seven of these 23, none of whom showed amplification in
the first tumour sample. DNA was also extracted from exfoliated cells in urine collected from five cases of
carcinoma in situ and c-erbB-2 amplification was demonstrated in one of these. No gene amplification was
identified in patients' lymphocytes, ten biopsies of normal urothelium and 22 various intravesical pathologies.
Increased expression of c-erbB-2 mRNA correlated with amplification of the gene. In addition, raised levels of
mRNA were seen in the absence of gene amplification in six tumours. Immunoblotting using the polyclonal
antibody 21N, raised against the c-terminus of the c-erbB-2 protein demonstrated increased amounts of a
185 kD immunoreactive protein in tumours with increased c-erbB-2 gene copy number compared with control
tissues. In some tumours with high c-erbB-2 gene copy number, a 155 kD immunoreactive protein not detected
in controls was expressed at higher level than the 185 kD protein. Immunocytochemistry using a monoclonal
antibody AB-3, raised against the c-terminus of the c-erbB-2 protein, showed a positive reaction in the
cytoplasm and cell membrane of tumours with gene amplification and in 40% of tumours with no ampli-
fication. An association was found between c-erbB-2 amplification and over-expression and the development of
tumour re-occurrences. We suggest that c-erbB-2 amplification and over-expression may provide a useful
molecular marker in transitional cell carcinoma of the bladder and merits further investigation as a potential
prognostic indicator.
Transitional cell carcinoma of the bladder is the fourth most
common cancer in males in the United Kingdom (HMSO,
1988; Scottish Health Statistics, 1988; DHSS, Belfast, 1988).
Between 1971 and 1984, the overall incidence of transitional
cell carcinoma of the bladder rose by 31% (OPCS, 1971-
1984) with a corresponding rise in annual mortality of 22%
between 1969 and 1987 (OPCS, 1969-1987). Available data
suggest that a subgroup of aggressive tumours (including
18% T,) is responsible for most of the morbidity and mortal-
ity (Pryor, 1973). In the past 20 years, there has been no
improvement in the management of transitional cell carcin-
oma, due in part to a failure to identify this sub-group of
patients at risk. At present, tumour grade and stage remain
the best prognostic indices but inter- and intra-observer
inconsistency rates of between 15 and 50% (Abel et al., 1988;
Ooms et al., 1983) limit their clinical application.
It is generally accepted that carcinogenesis is a multistep
process involving the accumulation of a number of genetic
changes over a period of many years (Foulds, 1975; Farber,
1984). The identification of the molecular events underlying
urothelial cell transformation may not only expand our
understanding of the natural history of the disease, but may
also present useful prognostic markers and potential targets
for therapy. In this context, changes in expression of the
epidermal growth factor receptor (EGFR) may represent a
useful marker. It has been shown that expression of the
EGFR measured by immunohistochemistry or ligand binding
is significantly higher in invasive (pT3) than in superficial
(pTj) bladder tumours (Neal et al., 1985; Berger et al., 1987;
Smith et al., 1989). This may indicate a role for this receptor
in bladder tumour progression, though to date there is no
indication that high levels of expression of EGFR in non-
invasive tumours is predictive of poor prognosis.
As part of a study aimed at identifying other molecular
lesions in transitional cell tumours, we have examined the
structure and expression of the proto-oncogene c-erbB-2.
This gene encodes a transmembrane protein with significant
homology to the epidermal growth factor receptor (c-erbB-l)
(King et al., 1985; Schechter et al., 1984, 1985; Bargmann et
al., 1986a). It is thought to represent the receptor for an as
yet unidentified ligand (Coussens et al., 1985; Yamamoto et
al., 1986) and was originally identified as an activated onco-
gene (neu) in ethyl and methylnitrosourea-induced rat neuro-
blastomas (Shih et al., 1981). In these rat tumours, oncogenic
activation results from a single base substitution in the
predicted transmembrane domain of the protein (Bargmann
et al., 1986b).
In human tumours however, over-expression and not
mutation of c-erbB-2, the human homologue of neu appears
to contribute to tumour development (Slamon et al., 1989;
Lemoine et al., 1990). Amplification and over-expression of
c-erbB-2 have been reported in a number of different human
tumours, including breast (King et al., 1985), salivary gland
(Semba et al., 1985), stomach and kidney (Yokota et al.,
1986) and ovary (Slamon et al., 1989). In breast and ovarian
carcinoma, c-erbB-2 is amplified in 25-30% of primary
tumours (Slamon et al., 1987, 1989), a direct correlation
between amplification and over-expression has been demon-
strated and also an association between amplification and
clinical outcome. In addition, over-expression of the protein
has been detected in the absence of amplification in 10% of
tumours.
We now show that amplification and over-expression of
c-erbB-2 is common in transitional cell carcinomas of the
urinary bladder. The incidence of amplification correlates
with tumour grade and in patients from whom repeated
tumour samples have been obtained, it appears that the
development of amplification may be associated with disease
progression. A preliminary report of these findings has
appeared elsewhere (Coombs et al., 1989).
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Materials and methods
Tissue samples
Samples were collected from patients undergoing cystoscopic
examination at University College Hospital, the Middlesex
Hospital, the Shaftesbury Hospital and St Peter's Hospital,
London. Tissue was cut with diathermy or 'cold' cup biopsy
forceps, and was removed from the bladder as soon as
possible, trimmed of debris and a representative sample
excised (including the base and attached normal tissue) for
histopathological assessment. The remainder was placed
immediately at -70°C. Tumour size ranged from 60 mg to
many grams but the majority (>80%) were small and were
processed as a single sample. Ten ml venous blood was
collected in lithium-heparin tubes, mixed well and placed at
-70°C. Cells from urine were obtained from freshly voided
samples by suction through 5 mm Whatman cellulose nitrate
filters and stored at - 70°C.
The tissues used are shown in Table I. Transitional cell
tumours were obtained from 82 patients and urothelium
subsequently diagnosed as carcinoma in situ from four
patients. For 23 patients, further biopsies were obtained on
at least one occasion. In addition, exfoliated cells were col-
lected from the urine of five patients with carcinoma in situ.
The histology of all samples reported in this series was
reviewed by a single pathologist.
Isolation ofDNA, RNA andprotein
DNA, RNA and protein were isolated from the same tumour
sample by a modification of the guanidine isothiocyanate
method (Coombs et al., 1990). Tissue was immersed in 4 M
guanidine isothiocyanate (maximum 0.15 g tissue ml-'),
chopped finely with a scalpel and rotated for a minimum of
4 h to ensure dissolution. The solution was then layered onto
a cushion of 5.7M caesium chloride and centrifuged at
150,000g at 20°C for 18 h. The guanidine isothiocyanate
phase containing protein and the guanidine/caesium chloride
interface containing the DNA were removed and dialysed at
4°C for 24 h against four changes of 100 mM ammonium
bicarbonate or 1 x TE (10 mM Tris-HCl, 1 mM EDTA
pH 8.0) respectively. Protein samples were frozen at -70°C
for 24 h then lyophilised to dryness, dissolved in buffer
[50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM
Dithiothreitol, 0.1% NP40 (+ 10% glycerol for prolonged
storage)] and quantitated by Coomassie blue staining (Brad-
ford, 1976). DNA was extracted twice with phenol, twice
with phenol:chloroform and once with chloroform, ethanol
Table I Tissues used in the study
Tissue Number ofspecimens
Transitional cell tumoursa
TCC Grade 1b 37
TCC Grade 2 32
TCC Grade 3 13
Carcinoma in situ (biopsy) 4
Carcinoma in situ (urine cells) 5
91
Control tissues and other tumours
Patients' peripheral blood lymphocytes 25
Macroscopically 'normal' urothelium from 39
tumour-bearing bladders ('field biopsies')
'Normal' urothelium from non tumour-bearing 10
bladders
Various intra-vesical pathologies 22
(schistosomiasis, catheter trauma, cystitis,
squamous carcinoma, adenocarcinoma,
infiltrating prostatic carcinoma)
Peripheral blood lymphocytes from volunteers 2
Cultured human dermal fibroblasts
aTumour samples listed represent the first specimen obtained from
each patient. Additional tumourbiopsies were obtained on one or more
occasions from 23 ofthe 82 patients with TCC. bTCC, transitional cell
carcinoma.
precipitated and dissolved in 1 x TE prior to quantitation
and use. The RNA pellet was washed in 70% ethanol, air
dried and dissolved in 300 Ll 0.3M sodium acetate pH 6.0
prior to precipitation with two volumes of absolute ethanol
and storage at -70°C. Lymphocyte DNA was prepared from
10ml whole blood following lysis of the red cells in 40 ml
lysis buffer (0.32 M sucrose, 10 mM Tris, HCI pH 7.5, 5 mM
MgCI2 and 1% Triton 100) on ice for 10min. White cells
were collected by centrifugation at 2,500g for 15 min at 4°C.
The cell pellet was lysed in 1 x TSE buffer (10 mM Tris-HCl,
100 mM NaCl, 1 mM EDTA, pH 8.0) containing 0.5% SDS
(0.75mlmlh' blood) and proteinase K (200figml-' blood)
and incubated with shaking at 55°C for 2 h. One tenth
volume 3 M sodium acetate was added and the lysate extract-
ed with phenol:chloroform (1:1), followed by chloroform,
ethanol precipitated and dissolved in 1 x TE prior to quanti-
tation and use.
Southern blotting
DNA samples were digested with EcoRI (Gibco BRL, Pais-
ley, Scotland) according to the manufacturer's instructions
and the fragments separated in 0.8% agarose gels. Gels were
stained with ethidium bromide and photographed prior to
capillary transfer (Southern, 1975) to Hybond-N membranes
(Amersham, Aylesbury, UK). Lambda DNA digested with
HindlIl was used as size markers and lymphocyte DNA from
normal volunteers or DNA from normal human dermal
fibroblasts were used as normal DNA controls on each gel.
Blots were baked at 80°C for 2 h and pre-hybridised and
hybridised (at 65°C) in 5 x SSPE (1 x SSPE = 0.18 M NaCl,
0.01 M sodium phosphate, 0.001 M EDTA, pH 7.7), 5 x Den-
hardt's solution, 0.5% sodium dodecyl sulphate (SDS) and
20tigml1l sonicated salmon sperm DNA with shaking.
Probes were labelled by random priming (Feinberg & Vogels-
tein, 1983) and used at 106 c.p.m. ml1- of hybridisation fluid.
Following washing to high stringency (0.1% SSPE and 0.1%
SDS at 65°C), blots were exposed to Hyperfilm MP (Amer-
sham) at 70°C with intensifying screens. Probes were
removed by incubation for 30 min in 0.4 M NaOH at 45°C
followed by incubation for 30 min in 0.1 x SSC (1 x SSC =
0.15 M NaCl, 0.015 M sodium citrate), 0.1% (w/v) SDS, 0.2 M
Tris-HCI pH 7.5 at 45°C.
Analysis ofgene amplification
Southern blots were hybridised sequentially with c-erbB-2,
thymidine kinase and p53 probes used singly, and were then
hybridised with two probes simultaneously (both c-erbB-2 +
thymidine kinase and c-erbB-2 + p53). c-erbB-2 maps to the
long arm of chromosome 17 (17 ql 1.2-ql2; Coussens et al.,
1985), thymidine kinase to the distal end of 17q (17q23.2-
q25.3; van Tuinen et al., 1987) and p53 to the short arm of
the same chromosome (17pl3.1; Benchimol et al., 1985).
Comparison of the relative signal obtained with c-erbB-2 and
p53 probes allows the presence of multiple copies of chromo-
some 17 to be distinguished from genuine amplification of
c-erbB-2 and comparison with the thymidine kinase signal
excludes 17q isochromosome formation and provides evi-
dence for localised amplification on 17q. The ratio of inten-
sity of the autoradiographic signal of c-erbB-2 and the cont-
rol gene probe was estimated in tumour samples and com-
pared to that in matched normal and independent normal
DNA controls. In control samples this ratio was taken as 1.
Photographs of the ethidium-stained gels prior to transfer
were also used as additional confirmation of gel loading. All
tumour DNAs were analysed on at least two different blots
and all blots were re-hybridised at least twice as described
above to exclude hybridisation artefacts. Autoradiographs
were assessed blind by three independent observers on two
separate occasions (this gives a minimum of 12 observations
on each tumour sample). The gene was scored as amplified
only when the results of at least 11 observations concurred.
These results were compared with analysis by laser densi-
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assessment but generated some false positives which could
not be confirmed by dilution analysis. Where enough DNA
was available, selected samples with amplification of c-erbB-2
were subjected to dilution analysis to obtain estimates of the
level of amplification. Amplification was classified as <3-
fold or >3-fold.
Northern blotting
Total cellular RNA was electrophoresed in 1% agarose/for-
maldehyde gels (modified from Thomas, 1980) and transfer-
red by capillary blotting to Hybond-N membranes. These
were pre-hybridised and hybridised in 5 x SSPE, 5 x Den-
hardt's solution, 0.5% SDS, 50% formamide and 20pg ml-'
sonicated salmon sperm DNA at 42°C. Filters were hybrid-
ised overnight with 106 c.p.m. ml-' radiolabelled probe, with
shaking at 42°C. A number of gels were stained with ethi-
dium bromide to compare loading and RNA integrity with
the results obtained with control probes.
Immunoblotting
Total cell protein was electrophoresed on 5% SDS-poly-
acrylamide gels (Laemmli, 1970) and transferred at 200 mA
to Hybond-C extra (Towbin et al., 1979). Parallel gels were
stained with Coomassie blue to assess protein loading. Fol-
lowing transfer, the membranes were blocked for 12 h with
10% bovine serum albumin (BSA) in phosphate buffered
saline (PBS) at room temperature. They were then rinsed in
PBS and incubated for 1 h with antiserum 21 N (see below)
(1/100 dilution) in PBS containing 1% BSA. Following
washes in PBS (2 x 10min), filters were incubated with
0.2 ; Ci ml-I251-protein A in PBS containing 1% BSA for
1 h at room temperature. The membranes were then washed
once in PBS, once in 0.1% NP40 in PBS and three times in
PBS, each for 10 min at room temperature. After air drying
they were wrapped in Saran wrap and exposed to Hyperfilm
MP between intensifying screens at - 70C for 24 h.
Immunocytochemistry
Immunocytochemistry was carried out using the indirect
immunoperoxidase technique (Hsu, 1981). Paraffin sections
(3-4 1tm) were cut from the blocks used for histopatho-
logical analysis. Sections were dewaxed in xylene and washed
in absolute methanol. Endogenous peroxidase activity was
blocked with 0.5% H202 followed by washing in tap water,
then distilled water at 37°C. The sections were trypsinised for
5 min at 37°C in mg ml-' crude porcine pancreas trypsin
type II (Sigma, Poole, UK), 1 mg ml-' CaCl2 in distilled
water adjusted to pH 7.8. Following washing for 5 min each
in water and two changes of TBS (25 mM Tris base, 138 mM
NaCl, 3.3 mM KCI) primary antibody (AB-3:1/500) was ap-
plied for 30 min followed by washing in TBS. The sections
were covered with biotinylated rabbit anti-mouse serum con-
taining 4% normal human serum for 30 min, then washed
with TBS. Sections were incubated in avidin-biotin perox-
idase complex (Dako Ltd, UK) for 30 min and then treated
with diaminobenzidine solution (0.6 mg ml ' in TBS pH 7.6
containing 0.03% H202) for 10min. Sections were counter-
stained with Mayer's haematoxylin, and mounted. Controls
included omission of the primary antibody and prior absorp-
tion of the primary antibody with the immunising peptide
(1 mg ml') at room temperature for 2 h.
Probes and antibodies
The probes used were the 700 bp BamHI-AccI fragment of
pMacl 17 (c-erbB-2, King et al., 1985) supplied by the
American Type Culture Collection, the 1.6 kb HindIII-EcoRI
fragment of pHTK2 (thymidine kinase, Lau & Kan, 1984)
kindly supplied by P. Goodfellow, a polymerase chain
reaction-generated full length cDNA of human p53 kindly
provided by Dr J. Jenkins and the 1.3 kb PstI fragment of
pRGAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase,
Fort et al., 1985).
Antibody 21N raised to a synthetic peptide at the c-
terminus (aal243-1255) of c-erbB-2 was generously provided
by Dr W. Gullick (Gullick et al., 1987). The monoclonal
antibody AB-3 (Oncogene Science) which was raised to a
synthetic 15 aa peptide (1242-1255) from the c-terminus of
human c-erbB-2 was used for immunohistochemical analyses
(van de Vijver et al., 1988).
Results
Amplification ofc-erbB-2
All DNA samples yielded a single 6.5 kb EcoRI fragment
which hybridised to the c-erbB-2 probe. No rearrangements
of the gene were detected in any specimens. Gene amplifi-
cation was observed in 12 of the initial tumour specimens
from the 82 patients with transitional cell carcinoma (Table
II). These included 1/37 grade 1 (2%) 5/32 grade 2 (16%)
and 6/13 grade 3 (46%) lesions. Amplification ranged from 2
to 15-fold. The association between tumour grade and c-
erbB-2 amplification was statistically significant (X2= 14.56;
0.005<P<0.01). In addition to the increased frequency of
amplification detected in patients with grade 2 and 3
tumours, there was an apparent association between the level
of amplification detected and tumour grade, all grade 3
tumours with amplification having >3-fold amplification.
This association between the degree of amplification and
tumour grade was also exemplified by a series of individual
samples prepared from different areas of a single large
tumour. A spectrum of amplification from none to approxi-
mately 5-fold was found in different areas of this tumour and
this correlated with the histological appearance of the
tumour which ranged from grade 1 exophytic tumour to
grade 3 solid invasive tumour.
Gene amplification was detected in seven of the 23 patients
(30%) from whom additional tumour samples were collected
on one or more occasions during a 2 year period of study.
We have used the term 're-occurrences' rather than 'recur-
rences' for such subsequent tumours, since the relationship
between these and the previous or primary tumour is at
present unclear. In these patients, amplification was detected
in a second or third specimen but not the initial tumour
specimen. These comprised 3/14 (21%) G.1 and 4/8 (50%)
G.2 tumours (Table III). The degree of amplification in-
creased in one of these patients from none in the first speci-
men to <3-fold in the second and >3-fold in the third
sample although all samples were assessed as grade 2. This
was associated with an increase in the number and frequency
of tumour re-occurrences in this patient.
Table II Amplification ofc-erbB-2 at time of first tumour sample
Grade Stage Amplification Total










3 P2 H 6/13 (46%)
3 P2 H
3 CiS H 1/9 (11%)
13/91 (14%)
aPost-surgical histopathological classification is according to the
TNM system (1978); bH, >3-fold amplification, L, <3-fold amplifi-
cation; cFor grade 1, 2 and 3 tumours x2= 14.56 (0.005<P<0.01).604 L.M. COOMBS et al.
Table III Amplification of c-erbB-2 in tumour 're-occurrences'
Tumour sample - grade andamplification
Patient la 2 3
1 1 1 (L)b _
2 2 2 (H)
3 2 2 (L) 2 (H)
4 2 2 (L)
5 2 2 2 (H)
6 1 1(L)_
7 1 1(L)-
Total = 7/23 patients with repeat samples
aColumn headings indicate first, second or third tumour sample;
bNumbers indicate tumour grade. Degree ofamplification is shown in
parenthesis.
In the four tissue samples diagnosed as carcinoma in situ, no
geneamplification wasdetected. In fivepatientswithcarcinOma
in situ, DNA was isolated from exfoliated cells in the urine and
one of these showed amplification of c-erbB-2. Amplification
was detected in only 1 of 39 macroscopically normal 'field
biopsies' from tumour-bearing bladders and not in any ofthe
other control tissues. Figure 1 shows a typical Southern blot
hybridised simultaneously to c-erbB-2 and thymidine kinase
probes showing 10-15-fold amplification in the tumours in
tracks a and b, 3-5-fold amplification in the sample in track c,
<3 fold amplification in the sample in track d from a different
area of the same tumour shown in track c and <3-fold
amplificationinthesampleintrackdfromadifferent areaofthe
sametumour shownintrackcand <3-foldamplification inthe
tumour in track e. Tumours in tracks f and g have no
amplification ofc-erbB-2. The related epidermal growth factor
receptor gene(c-erbB-1) wasassessed by Southernblottingin40
tumours in this series. No amplification or re-arrangement of
the gene was detected.
Expression ofc-erbB-2 RNA
RNA was obtained from tumours of 40 patients, six on two
consecutive occasions (Table IV). Of the 40 initial tumours,
six showed c-erbB-2 amplification. Northern blots were hy-
bridised sequentially with a c-erbB-2 probe and then with a
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe
as a control. Although the 1.4 kb transcript of GAPDH
appeared to confirm equal RNA loading, ethidium bromide
staining of the gels suggested loss of higher molecular weight
species in the tumour samples and in some cases reversal of
the normal 28S:18S band ratio. The pattern of non-specific
binding of the GAPDH probe to the 28S ribosomal band
correlated more closely with loading of higher molecular
weight species and this was used to assess RNA loading. A
single c-erbB-2 transcript of 4.5 kb was detected in all sam-
ples. In Figure 2, the c-erbB-2 signal was compared with
non-specific binding to the 28S band and with the 1.4kb
transcript of GAPDH. Despite variable degrees of degrada-
tion, increased levels of c-erbB-2 mRNA can be identified in
the tumours in tracks a, f, g, j and k. The level of transcript
in track h appeared raised on this blot, but was equivocal on
other blots and was not scored as over-expressed. RNA
extracted from confluent human dermal fibroblasts in culture
was used as a control. The levels of expression seen were
comparable to those seen in normal urothelium. All six
tumours with gene amplification showed increased levels of
transcript compared with normal urothelial controls. In addi-
tion, in six tumours there appeared to be raised levels of
transcript in the absence of gene amplification and these
tumours were all of poor grade or deteriorating clinical
status.
Six of the samples analysed were from tumour re-occur-
rences. Two of these six pat,nts showed gene amplification
in the second tumour sample. In one patient, increased trans-
cipt levels appeared to precede gene amplification. Three of
the other four RNA samples from re-occurrences had in-
creased transcript levels which were not detected in the initial
sample from the same patient, though none showed gene
amplification.










Figure 1 Southern blot of bladder tumour DNAs hybridised
with c-erbB-2 and thymidine kinase probes. Each track contains
101ag DNA digested with EcoRI. HDF, cultured human dermal
fibroblast DNA control; M, lambda-HindIII size markers; Tracks
d and e represent different areas from a single tumour.
Table IV Expression ofc-erbB-2 mRNA in initial tumour samples
mRNA level
c-erbB-2 copy numbera Normal Elevated Total
Normal 28b 6 34
Amplified 0 6 6
40
aGene copy number determined by Southern blotting; bNumbers of
tumours showing normal or elevated c-erbB-2 RNA levels.
HDF




Figure 2 Northern blot of tumour RNAs. Each track contains
15yig total RNA. In the top panel the blot was hybridised to
c-erbB-2 probe. In the bottom panel, the same blot was hyb-
ridised to GAPDH.
Expression ofc-erbB-2protein
Immunoblotting was performed on a selection of protein
samples from tumours with varying degrees of amplification
and overexpression and compared with controls. The signal
intensity from tumours was compared with that from 'field'
biopsies and loading was assessed by Coomassie blue staining
of identical gels run in parallel. Protein from confluent
SKBR-3 cells, a breast carcinoma cell line which contains a
highly amplified and over-expressed c-erbB-2 gene (van de
Vivjer et al., 1987) was used as a positive control. Over-
expression of the expected 185 kD c-erbB-2 immunoreactive
protein correlated with amplification. In many samples, a
155 kD immunoreactive protein was also detected. Those
tumours with high gene copy number expressed relatively
more of the 155 kD product that the 185 kD protein. Neither
the 185 kD nor the 155 kD bands were seen when the anti-
body 21N was pre-incubated with the immunising peptide.
Figure 3 shows a typical Western blot. The tumour in track ac-erbB-2 AMPLIFICATION IN BLADDER CARCINOMA 605
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Figure 3 Top panel is an immunoblot of c-erbB-2 protein in
bladder tumours (40#Ag total cellular protein per track). Lower
panel shows an identical gel run in parallel and stained with
Coomassie blue to assess loading.
and SKBR-3, both of which have high c-erbB-2 gene copy
number, show high levels of expression, predominantly of the
155 kD product. A faint 155 kD band can be visualised in
track k from a tumour which also contained an amplified
c-erbB-2 gene. Comparison of the Coomassie blue stain and
field biopsies from the same patient shows that the tumours
in tracks d, e, n and r which have increased copy number of
the c-erbB-2 gene also over-express the 185 kD immunore-
active product. The tumour in track g and the field biopsy in
track h are from the same cystectomy specimen. Both con-
tained amplified c-erbB-2 genes on Southern blotting and
both showed similar levels of p185 expression. Immunoblot-
ting was the least sensitive method of quantitation of over-
expression and was therefore only applied to a limited
number of samples.
The monoclonal antibody AB-3 raised against the c-term-
inus of c-erbB-2 was used to detect the c-erbB-2 protein
product in sections of paraffin-embedded specimens from the
initial tumour samples of 73 patients. 21N was used on some
specimens for comparison, with similar results. Reactivity
was confined to the cytoplasmic membrane of the luminal
surface of mature superficial cells in normal urothelium and
was very faint. All tumours which had been shown to have
c-erbB-2 amplification showed immunoreactivity. Various
distributions of the c-erbB-2 protein were observed. All
tumour cells which reacted positively showed cytoplasmic
localisation of the protein. In tumours with high levels of
gene amplification, membrane and cytoplasmic reactivity was
present in most tumour cells and the latter predominated
(Figure 4a and c). Both cytoplasmic and membrane reactivity
was abolished by pre-incubation of the antibody with the
immunising peptide and no product was detected in samples
where the primary antibody was omitted (Figure 4b). Those
samples in which low levels of amplification had been dem-
onstrated showed focal reactivity in discrete areas of the
tumour, suggesting a heterogeneous distribution of cells
which over-express c-erbB-2. In 40% of tumours which
gene amplification, discrete clusters of cells reacted with the
antibody though no over-expression of c-erbB-2 had been
detected by other methods. These clusters of cells were often
grouped on the luminal surface of the tumour. In most of
these latter cases, the number of positive cells was small.
When c-erbB-2 immunoreactivity was compared with
tumour grade, it was found that not only a large proportion
of grade 3 tumours but also more than 40% of both grade 1
and grade 2 tumours showed focal reactivity (Table V). In
addition seven of 20 field biopsies showed focal positive
reactivity. Three of these were from bladders which con-
tained tumours with no positive cells.
Patientfollow-up
Complete follow-up data for this group of patients are not
yet available. However clinical information for the 2 year
period of tissue collection and for 1 year afterwards has been
assessed and compared with results for c-erbB-2 expression
for a subset of 56 patients. Sixteen of 35 patients in whom
Figure 4 Immunohistochemical localisation of c-erbB-2 protein
in bladder tumours detected with the monoclonal antibody AB3.
a, Membrane and cytoplasmic reactivity in most cells of a
tumour which had multiple gene copies and high levels of c-erbB-
2 mRNA; b, control in which primary antibody was omitted.
Section from same area of the tumour shown in a; c, higher
magnification of tumour shown in a. Both membrane and gran-
ular cytoplasmic reactivity are present. All tumour cells contain
reactive material, but there is heterogeneity in the amount of
product detected. Bar = 50jim.
Table V Association ofc-erbB-2 immunohistochemical reactivity and




Grade 1 12 17 41
Grade 2 11 7 61
Grade 3 6 3 67
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c-erbB-2 over-expression had been demonstrated have died of
their disease or undergone radical therapy (intravesical BCG,
X-irradiation or cystectomy) compared with 6/21 patients
with normal expression levels. Of the remaining patients,
14/19 with c-erbB-2 over-expression and 5/15 with normal
levels of c-erbB-2 expression had superficial re-occurrences at
the last cystoscopic examination.
Discussion
The need for prognostic markers for superficial bladder
tumours has long been recognised. To date few potential
markers have been identified, and none have good predictive
value (Raghavan et al., 1990). Expression of EGFR (Neal et
al., 1985; Berger et al., 1987; Smith et al., 1989) shows a
significant relationship with tumour grade and stage. A few
low grade superficial tumours have been reported to have
increased expression of EGFR (Berger et al., 1987) but the
possible prognostic significance of this finding is at present
unknown. Mutated ras genes (Fujita et al., 1985; Visvana-
than et al., 1988) and specific deletions of the short arm of
chromosome 11 (Fearon et al., 1985) have been identified in
a proportion of bladder tumours, though neither of these
molecular markers has been shown to have prognostic signi-
ficance.
The small amount of tissue available and the identification
of low level gene amplification in human tumour material
presents a number of technical difficulties. These have been
discussed recently by Slamon et al. (1989) and include the
need to use separate techniques to isolate each component of
expression, dilution of tumour cells by normal cells, degrada-
tion of DNA, tumour cell aneuploidy, unevenness of gel
loading and local variations in transfer and hybridisation.
We have avoided these latter problems by the preparation of
multiple blots where feasible, simultaneous hybridisation with
c-erbB-2 and control probes, repeat hybridisations to confirm
results, careful assessment of gel loading using ethidium-
staining and control probes, and the use of probes on each
arm of chromosome 17. These problems become less impor-
tant when mRNA and protein levels of the gene of interest
are studied simultaneously. We have extended the guanidine
isothiocyanate method for DNA and RNA isolation to in-
clude isolation of protein from the same sample (Coombs et
al., 1990). This maximises the use of small samples and
ensures that the DNA, RNA and protein samples compared,
come from the same area of the tumour. The importance of
this local sampling was exemplified clearly by our findings on
the tumour from one patient, where different areas from the
same large tumour showed different levels of c-erbB-2 gene
amplification and expression. This points to the need for
multiple samples with matched pathological assessment from
large tumours. Our finding that intact DNA can be isolated
from exfoliated cells collected from urine may provide the
basis for a non-invasive assay in the future.
We have shown that amplification and over-expression of
c-erbB-2 in transitional cell tumours, as in a number of
epithelial tumour types, is a frequent event. Twelve out of 86
(14%) had an amplified gene at the time of first biospy. This
frequency is in the range (11-30%) reported for breast and
ovarian tumours (Zhou et al., 1989; Slamon et al., 1987,
1989). Amplification was more frequent and gene copy
number higher in high grade tumours. The correlation found
between tumour grade and gene amplification suggests that
amplification is linked directly or indirectly to disease pro-
gression. The absence of gene amplification in the control
samples and field biopsies shows that amplification of c-erbB-
2 is specific to overt transitional cell carcinoma in the urinary
bladder. In the only field biopsy in which gene amplification
was detected, it was found that most of the bladder mucosa
in this cystectomy specimen was replaced by tumour.
The patients from whom additional biopsies were obtained
represented a random group of patients. In this group, 7/23
patients developed amplification during the course of the
study and although this was not associated with increased
tumour grade, it appeared to be associated with disease
progression. We have avoided the term 'recurrences' for
those tumours that developed subsequent to the initial resec-
tion, since in many patients they occur at different sites in the
bladder and often develop within an unstable urothelium
which shows widespread field changes. Thus, in many cases
such tumours are likely to represent new 'occurrences'. It is
clear that future studies concerning the progression of neo-
plastic disease in the bladder must address this question in
detail.
If amplification of a gene is relevant to the pathogenesis of
the disease, changes in gene expression must be expected.
Some amplified genes are not expressed in the relevant
tumours, e.g. c-erbA, which in breast tumours is often co-
amplified with c-erbB-2 (Tavassoli et al., 1989). Although our
assessment of levels of c-erbB-2 transcript were hampered by
the variable levels of RNA degradation, it was possible to
demonstrate that levels of c-erbB-2 transcript parallelled
amplification and that some high grade or clinically aggres-
sive tumours had raised levels of transcript in the absence of
gene amplification. In one case, raised levels of mRNA
preceded the detection of gene amplification in a subsequent
biopsy.
Immunoblotting revealed two immunoreactive proteins at
185 kD and approximately 155kD. De Potter et al. (1989)
have suggested that these may represent the c-erbB-2 cell
membrane protein and a 155 kD protein associated with the
mitochondrial membrane. The smaller of these may represent
a partially glycosylated form of the protein since inhibition of
N-linked glycosylation by tunicamycin has been shown to
produce an immunoprecipitable protein of 155-160kD in
human cells which express c-erbB-2 (Akiyama et al., 1986).
Immunoblotting was the least sensitive assay of c-erbB-2
expression. Only large differences could be demonstrated
clearly. This finding is in keeping with those of Slamon et al.
(1989) in breast tumours and may reflect dilution of tumour
cell protein by variable amounts of protein from other cells,
stromal elements and necrotic debris.
Immunocytochemistry showed that the c-erbB-2 gene pro-
duct is confined to the luminal membrane of mature surface
cells in normal urothelium. In bladder tumours, we have
found both cytoplasmic and membrane reactivity. In contrast
to reports on breast tumours, most c-erbB-2 protein in these
transitional cell tumours was cytoplasmic, and this was parti-
cularly pronounced in tumours with high gene copy number
and mRNA expression. In this context, it may be significant
that high levels of the 155 kD protein were detected in such
tumours. Good correlation was found between the number of
positive cells, the degree of gene amplification and amount of
mRNA detected. Granular cytoplasmic reactivity, though less
prominant that membrane reactivity, has been demonstrated
in breast tumours using antibodies to different epitopes on
the protein (both internal and external) (Berger et al., 1988;
Gusterson et al., 1988; van de Vijver et al., 1988) and this
correlates with c-erbB-2 gene amplification and membrane
reactivity (Gusterson et al., 1988).
In colon carcinomas, c-erbB-2 protein appears to be prim-
arily cytoplasmic and correlates with gene amplification
(D'Emilia et al., 1989). The close correlation of amplificaiton
of c-erbB-2 and cytoplasmic immunoreactivity in the present
and other studies argues that the cytoplasmic product does
represent a form of the c-erbB-2 protein. It will be important
to examine these two protein forms and cellular location
more fully.
The significance of the heterogeneous distribution of over-
expression of the c-erbB-2 protein is not clear. Possible ex-
planations include technical artefacts, local conditions within
the tumour which may induce or inhibit c-erbB-2 expression
and the possibility that some tumours represent mosaics of
cells with different molecular lesions. McCann et al. (1990) in
a study of 48 bladder tumours, reported c-erbB-2 staining in
only one tumour. The reason for this discrepancy is not clear
but may reflect differences in scoring thresholds and/or
criteria. Wright et al. (1990) have recently reported that in a
series of 44 bladder tumours, 36% showed c-erbB-2 immuno-c-erbB-2 AMPLIFICATION IN BLADDER CARCINOMA 607
cytochemical staining on frozen tissues sections. Our findings
on paraffin-embedded material show similar frequencies.
These latter authors reported a significant reduction in stain-
ing sensitivity on paraffin-embedded material which may sug-
gest that the apparent differences between our findings and
those of McCann et al. (1990) are indeed attributable to
differences in scoring thresholds.
Forty percent of tumours with no detectable c-erbB-2
amplification or over-expression which could be detected by
Northern or Western analysis showed immunoreactivity.
Similar findings have been reported in breast tumours with
no gene amplification (Slamon et al., 1989; Berger et al.,
1988). This suggests that c-erbB-2 may be implicated in the
development of a higher proportion of breast and bladder
tumours than is suggested by the identification of gene ampli-
fication alone. Thus, immunocytochemistry may be the most
sensitive assay for future studies.
The function of the c-erbB-2 gene product in normal and
transformed epithelial cells remains unknown, though its fre-
quent over-expression in only certain tumours and high level
expression in only certain normal cell types e.g. colon (Cohen
et al., 1989) indicates a likely tissue specific role. Binding of
EGF to its receptor leads to an increase in the phosphoryla-
tion and tyrosine kinase activity of c-erbB-2 (Akiyama et al.,
1988). It has also been shown that over-expression of EGFR
and c-neu in NIH3T3 cells is sufficient for transformation
(Kokai et al., 1989). This interaction suggests that in the
bladder, where surface cells are bathed in EGF, over-express-
ion of either or both of these receptor proteins might lead to
a proliferative advantage. In this case, therapies based on
receptor targeting may be particularly useful.
Since 25% of transitional cell tumours progress clinically
during the first 3 years after presentation and only 7%
during the subsequent 7 years (Pryor, 1973), it should be
possible to assess the prognostic significance of c-erbB-2 ex-
pression within a relatively short period of time. It was
notable that amplification was detected in a superficial grade
1 tumour and over-expression in a relatively large subset of
grade 1 tumours. Follow-up of these patients will be of
particular interest. Since inaccuracies in the assessment of
grade and stage prevent their use as indices of progression,
evaluation ofc-erbB-2 as a prognostic marker will depend on
complete clinical follow-up of a large series of patients.
Our preliminary results, based on clinical data available
for the period of 2 years during which tissues were collected
and for 1 year following collection of the last samples
indicate that c-erbB-2 over-expression may be associated with
the incidence of tumour re-occurrences and with advancing
disease. The finding that c-erbB-2 over-expression appears to
precede disease progression suggests that this may represent a
true prognostic indicator in transitional cell carcinoma.
We are extremely grateful to the Consultant surgeons and their staff
who co-operated in this study. We also thank Dr G. Currie for
valuable discussions, encouragement and advice and Mrs J. Marr for
careful preparation of the manuscript.
References
ABEL, P.D., HENDERSON, D., BENNETT, M.K., HALL, R.R. & WIL-
LIAMS, G. (1988). Differing interpretations by pathologists of the
pT category and grade of transitional cell cancer of the bladder.
Br. J. Urol., 62, 339.
AKIYAMA, T., SUDO, C., OGAWARA, H., TOYOSHIMA, K. & YAMA-
MOTO, T. (1986). The product of the human c-erbB-2 gene: a
185 kilodalton glycoprotein with tyrosine kinase activity. Science,
232, 1644.
AKIYAMA, T., SAITO, T., OGAWARA, H., TOYOSHIMA, K. & YAMA-
MOTO, T. (1988). Tumour promoter and epidermal growth factor
stimulate phosphorylation ofthe c-erbB-2 gene product in MKN-
7 human adenocarcinoma cells. Mol. & Cell. Biol., 8, 1019.
BARGMANN, C.I., HUNG, M.-C. & WEINBERG, R.A. (1986a). The neu
oncogene encodes an epidermal growth factor receptor-related
protein. Nature, 319, 226.
BARGMANN, C.I., HUNG, M.-C., & WEINBERG, R.A. (1986b) Multi-
ple independent activations of the neu oncogene by a point
mutation altering the transmembrane domain of p185. Cell, 45,
649.
BENCHIMOL, S., LAMB, P., CRAWFORD, L.V. & 4 others (1985).
Transformation associated p53 protein is encoded by a gene on
human chromosome 17. Somatic Cell Mol. Genet., 11, 505.
BERGER, M.S., GREENFIELD, C., GULLICK, W.J. & 5 others (1987).
Evaluation of epidermal growth factor receptors in bladder
tumours. Br. J. Cancer, 56, 533.
BERGER, M.S., LOCHER, G.W., SAURER, S. & 4 others (1988). Cor-
relation of c-erbB-2 gene amplification and protein expression in
human breast carcinoma with nodal status and nuclear grading.
Cancer Res., 48, 1238.
BRADFORD, M. (1976). A rapid and sensitive method for the quanti-
tation ofmicrogram quantities ofprotein utilising the principle of
protein-dye binding. Analytical Biochem., 72, 248.
COHEN, J.A., WEINER, D.B., MORE, K.F. & 5 others (1989). Expression
pattern of the neu (NGL) gene-encoded growth factor receptor
protein(p185neU) in normal and transformed epithelial tissues ofthe
digestive tract. Oncogene, 4, 81.
COOMBS, L.M., KNOWLES, M.A. &MILROY, E. (1989). Her2 (c-erbB-2,
neu, Macl 17) amplification and expression in transitional cell
carcinoma. Urological Res., 17, 345.
COOMBS, L.M., PIGOTT, D., PROCTOR, A., EYDMANN, M., DENNER,
J. & KNOWLES, M.A. (1990). Simultaneous isolation of DNA,
RNA and antigenic protein exhibiting kinase activity from small
tumour samples using guanidine isothiocyanate. Analytical
Biochem., 188, 338.
COUSSENS, L., YANG-FENG, T.L., LIAO, Y.-C. & 9 others (1985).
Tryosine kinase receptor with extensive homology to EGF receptor
shareschromosomal location with neuoncogene. Science,230, 1132.
D'EMILIA, J., BULOVAS, K., D'ERCOLE, K., WOLF, B., STEELE, G. Jr. &
SUMMERHAYES, I.C. (1989). Expression of the c-erbB-2 gene
product (pl85) at different stages of neoplastic progression in the
colon. Oncogene, 4, 1233.
DE POTTER, C.R., QUATACKER, J., MAERTENS, G. & 5 others (1989).
Thesubcellularlocalisation ofthe neuprotein in human normal and
neoplastic cells. Int. J. Cancer, 44, 969.
FARBER, E.(1984). Themultistepnatureofcancerdevelopment. Cancer
Res., 44, 4217.
FEARON, E.R., FEINBERG, A.P., HAMILTON, S.H. & VOGELSTEIN, B.
(1985). Loss ofgenes on the short arm ofchromosome 11 in bladder
cancer. Nature, 318, 377.
FEINBERG, A.P. &VOGELSTEIN, B. (1983). A technique for radiolabel-
ing DNA restriction endonuclease fragments to high specific
activity. Analytical Biochem., 132, 6.
FORT, Ph., MARTY, L.,PIECHACZYK, M. &4others (1985). Various rat
adult tissues express only one major mRNA species from the
glyceraldehyde3-phosphate-dehydrogenase multigenicfamily. Neu-
cleic Acids Res., 13, 1431.
FOULDS, L. (1975). Neoplastic Development, I & 2. Academic Press:
London.
FUJITA, J., SRIVASTAVA, S.K., KRAUS, M.H., RHIM, J.S., TRONICK,
S.R. & AARONSON, S.A. (1985). Frequency ofmolecular alterations
affectingrasproto-oncogenes inhumanurinarytracttumours. Proc.
Nati Acad. Sci. USA, 82, 3849.
GULLICK, W.J., BERGER, M.S., BENNETT, P.L.P., ROTHBARD, J.B. &
WATERFIELD, M.D. (1987). Expression of the c-erbB-2 protein in
normal and transformed cells. Int. J. Cancer, 40, 246.
GUSTERSON, B.A., GULLICK, W.J., VENTER, D.J. & 5 others (1988).
Immunohistochemical localisation of c-erbB-2 in human breast
carcinomas. Molecular & Cellular Probes, 2, 383.
HSU, S.M., RAINE, L. & FANGER, H. (1981). Use of avidin-biotin-
peroxidase complex (ABC) in immunoperoxidase techniques: a
comparison between ABC and unlabelled antibody (PAP) proce-
dures. J. Histochem. Cytochem., 29, 577.
KING,C.R.,KRAUS, M.H.&AARONSON, S.A.(1985). Amplification ofa
novel v-erbB relatedgene inahumanmammarycarcinoma. Science,
229, 974.
KOKAI, Y., MYERS, J.N., WADA, T. & 5 others (1989). Synergistic
interaction ofpl85c-neu and the EGF receptor leads to transforma-
tion of rodent fibroblasts. Cell, 58, 287.
LAEMMLI, U.K. (1970). Cleavage of structural proteins during the
assembly of the head of Bacteriophage T4. Nature, 227, 680.
LAU, Y.F. &KAN, Y.W.(1984). Directisolation ofthefunctional human
thymidine kinase genewithacosmid shuttlevector. Proc. NatlAcad.
Sci. USA, 81, 414.608 L.M. COOMBS et al.
LEMOINE, N.R., STADDON, S., DICKSON, C., BARNES, D.M. & GUL-
LICK, W.J. (1990). Absence of activating transmembrane muta-
tions in the c-erbB-2 proto-oncogene in human breast cancer.
Oncogene, 5, 237.
MCCANN, A., DERVAN, P.A., JOHNSTON, P.A., GULLICK, W.J. &
CARNEY, D.N. (1990). c-erbB-2 oncoprotein expression in prim-
ary human tumours. Cancer, 65, 88.
NEAL, D.E., MARSH, C., BENNETT, M.K. & 4 others (1985). Epider-
mal growth factor receptors in human bladder cancer: compari-
son of invasive and superficial tumours. Lancet, i, 366,
OFFICE OF POPULATION CONSENSUSES AND STUDIES, M.B.1 1971-
1984. Cancer Statistics. HMSO.
OFFICE OF POPULATION CONSENSUSES ANDSTUDIES, D.H.1 1969-
1987. Mortality Statistics. HMSO.
OOMS, E.C.M., ANDERSON, W.A.D., ALONS, C.L., BOON, M.E. &
VELHUIZEN, R.W. (1983). Analysis of the performance of patho-
logistsin thegradingofbladdertumours. Human Pathology, 14, 140.
PRYOR, J.P. (1973). Factors influencing the survival of patients with
transitional cell tumours oftheurinarybladder. Br. J. Urol.,45, 586.
RAGHAVAN, D., SHIPLEY, W.U., GARNICK, M.B., RUSSELL, P.J. &
RICHIE, J.P. (1990). Biology and management ofbladder cancer. N
Eng. J. Med., 322, 1129.
SCHECHTER, A.L., STERN, D.F., VAIDYANATHAN, L. & 4 others
(1984). The neu oncogene: an erb-B-related gene encoding a
185,000-Mr tumour antigen. Nature, 312, 513.
SCHECHTER, A.L., HUNG, M.-C., VAIDYANATHAN, L. & 5 others
(1985). The neu gene: an erbB-homologous gene distinct from and
unlinked to the gene encoding the EGF receptor. Science, 229, 976.
SEMBA, K., KAMATA, N.,TOYOSHIMA, K. & YAMAMOTO,T. (1985). A
v-erbB-related protooncogene, c-erbB-2, isdistinct from thec-erbB-
1/epidermalgrowthfactor-receptorgeneandisamplifiedinahuman
salivary gland adenocarcinoma. Proc. Natl Acad. Sci. USA, 82,
6497.
SHIH, C., PADHY, L.C., MURRAY, M. & WEINBERG, R.A. (1981).
Transforming genes ofcarcinomas and neuroblastomas introduced
into mouse fibroblasts. Nature, 290, 261.
SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A. &
MCGUIRE, W.L.(1987). Human breastcancer: correlation ofrelapse
and survival with amplification of the HER-2/neu oncogene.
Science, 235, 117.
SLAMON, D.J., GODOLPHIN, W., JONES, L.A. & 8 others (1989). Studies
of the Her2/neu proto-oncogene in human breast and ovarian
cancer. Science, 244, 707.
SMITH, K., FENNELLY, J.A., NEAL, D.E., HALL, R.R. & HARRIS, A.L.
(1989). Characterization and quantitation ofthe epidermal growth
factor receptor in invasive and superficial bladder tumours. Cancer
Res., 49, 5810.
SOUTHERN, E.M. (1975). Detection ofspecific sequences among DNA
fragments separated by gel electrophoresis. J. Mol. Biol., 98, 503.
TAVASSOLI, M., QUIRKE, P., FARZANEH, F., LOCK, N.J., MAYNE, L.V.
&KIRKHAM,N.(1989). c-erbB-2/c-erbAco-amplificationindicative
oflymph node metastasis, and c-myc amplification ofhigh tumour
grade in human breast carcinoma. Br. J. Cancer, 60, 505.
THOMAS, P. (1980). Hybridization ofdenatured RNA and small DNA
fragments transferred to nitrocellulose. Proc. Nati Acad. Sci. USA,
77, 5201.
TOWBIN, H., STAEHELIN, T. & GORDON, J. (1979). Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose
sheets: procedureandsomeapplications. Proc. NatiAcad. Sci. USA,
76, 4350.
VAN DE VIJVER, M., VAN DE BERSSELAAR, R., DEVILEE, P., CORNE-
LISSE, C., PETERSE, J. &NUSSE, R. (1987). Amplification ofthe neu
(c-erbB-2) oncogene in human mammary tumors is relatively
frequent and is often accompanied by amplification of the linked
c-erbA oncogene. Mol. & Cell. Biol., 7, 2019.
VAN DE VIJVER, M.J., PETERSE, J.L., MOOI, W.J. & 4 others (1988).
Neu-protein overexpression in breast cancer: association with
comedo-type ductal carcinoma in situ and limited prognostic value
in stage II breast cancer. New Eng J. Med., 319, 1239.
VAN TUINEN, P., RICH, D.C., SUMMERS, K.M. & LEDBETTER, D.H.
(1987). Regional mapping panel for human chromosome 17:
application to neurofibromatosis type I. Genomics, 1, 374.
VISVANATHAN, K.V., POCOCK, R.D. & SUMMERHAYES, I.C. (1988).
Preferential and novel activation of H-ras in human bladder
carcinomas. Oncogene Res., 3, 77.
WRIGHT, C.,MELLON, D.E.,NEAL, D.E.,JOHNSON,P.,CORBETT, I.P. &
HORNE, C.H.W. (1990). Expression ofc-erbB-2 protein product in
bladder cancer. Br. J. Cancer, 62, 764.
YAMAMOTO, T.,IKAWA, S.,AKIYAMA, T. &5 others (1986). Similarity
ofprotein encodedbythehumanc-erbB-2genetoepidermal growth
factor receptor. Nature, 319, 230.
YOKOTA, J., YAMAMOTO, T., TOYOSHIMA, K. & 4 others (1986).
Amplification ofc-erbB-2 oncogene in human adenocarcinomas in
vivo. Lancet, i, 765.
ZHOU, D.-J., AHUJA, H. & CLINE, M.J. (1989). Proto-oncogene abnor-
malities in human breast cancer: c-ERBB-2 amplification does not
correlate with recurrence ofdisease. Oncogene, 4, 105.